2. Search Result
Search Result
Pathways Recommended: Immunology/Inflammation
Results for "

systemic inflammation

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

4

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3612
    CTCE-0214

    		CXCR Inflammation/Immunology
    CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research .
    CTCE-0214
  • HY-139567
    Afimetoran

    BMS-986256

    		 Toll-like Receptor (TLR) NF-κB Apoptosis Inflammation/Immunology
    Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable TLR7/8 antagonist. Afimetoran (BMS-986256) can inhibit TLR7/8 activation of the NF-κB pathway and reverse TLR7 mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus) .
    Afimetoran
  • HY-107575
    TLR4-IN-C34
    Maximum Cited Publications
    9 Publications Verification

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    TLR4-IN-C34 is an orally active TLR4 inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis .
    TLR4-IN-C34
  • HY-157227
    VPC01091.4

    VPC4

    		 TRP Channel Inflammation/Immunology
    VPC01091.4 (VPC4) is a TRPM7 inhibitor and blocks TRPM7 current at low micromolar concentrations. VPC01091.4 is an efficacious anti-inflammatory agent that arrests systemic inflammation in vivo .
    VPC01091.4
  • HY-P99505
    Ziltivekimab

    COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis .
    Ziltivekimab
  • HY-174270
    NLRP3-IN-79

    		NOD-like Receptor (NLR) NEKs Inflammation/Immunology
    NLRP3-IN-79 (Compound B6) is a selective NLRP3 inflammasome inhibitor with an IC50 value of 10.69 nM. NLRP3-IN-79 blocks the assembly of the NLRP3 inflammasome by disrupting the NEK7-NLRP3 interaction. NLRP3-IN-79 is promising for research of NLRP3-driven inflammatory diseases such as systemic inflammation, peritonitis, and colitis .
    NLRP3-IN-79
  • HY-139719
    IMD-biphenylC

    		NF-κB Inflammation/Immunology
    IMD-biphenylC is a novel imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylC
  • HY-139718
    IMD-biphenylB

    		NF-κB Inflammation/Immunology
    IMD-biphenylB is a potent imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylB
  • HY-147374
    Bromodomain inhibitor-9

    		Epigenetic Reader Domain Metabolic Disease Inflammation/Immunology
    Bromodomain inhibitor-9 is a Bromodomains inhibitor that selectively inhibits BRD4-1 (Kd: 12 nM). Bromodomain inhibitor-9 can be used in the research of diseases or conditions associated with systemic or tissue inflammation, lipid metabolism, fibrosis or chronic autoimmune diseases .
    Bromodomain inhibitor-9
  • HY-149700
    ROCK2-IN-7

    		ROCK MMP STAT Others
    ROCK2-IN-7 is a kinase inhibitor targeting to ROCK2. ROCK2-IN-7 inhibits ROCK2/pSTAT3 Signaling. ROCK2-IN-7 suppresses systemic immunity activation and attenuates inflammation in psoriasis model .
    ROCK2-IN-7
  • HY-P1717B
    AMY-101 acetate
    4 Publications Verification

    Cp40 acetate

    		 Complement System SARS-CoV Inflammation/Immunology
    AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
    AMY-101 acetate
  • HY-156367
    RIPK1-IN-16

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis .
    RIPK1-IN-16
  • HY-P1717
    AMY-101

    Cp40

    		 Complement System SARS-CoV Inflammation/Immunology
    AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
    AMY-101
  • HY-P1717A
    AMY-101 TFA
    4 Publications Verification

    Cp40 TFA

    		 Complement System SARS-CoV Inflammation/Immunology
    AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
    AMY-101 TFA
  • HY-W092043
    TLR4-IN-C34-C2-COOH
    1 Publications Verification

    		 PROTAC Linkers Toll-like Receptor (TLR) Inflammation/Immunology
    TLR4-IN-C34-C2-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34 (HY-107575). TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .
    TLR4-IN-C34-C2-COOH
  • HY-145245
    TLR4-IN-C34-C2-amide-C6-OH

    		PROTAC Linkers Toll-like Receptor (TLR) Inflammation/Immunology
    TLR4-IN-C34-C2-amide-C6-OH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .
    TLR4-IN-C34-C2-amide-C6-OH
  • HY-125792
    Nexinhib20

    		Reactive Oxygen Species (ROS) Ras Integrin Cardiovascular Disease Inflammation/Immunology
    Nexinhib20 is an inhibitor that targets the interactions of Rab27a-JFC1 (IC50: 2.6 μM) and Rac-1-GTP. Nexinhib20 can inhibit neutrophil exocytosis, adhesion, and β2 integrin activation, and has anti-inflammatory activity. Nexinhib20 can be used in the research of diseases such as systemic inflammation and myocardial ischemia-reperfusion injury .
    Nexinhib20
  • HY-402361
    TERT activator-1

    		MEK ERK AP-1 Neurological Disease Inflammation/Immunology
    TERT activator-1 is a small molecule activator of telomerase reverse transcriptase (TERT). TERT activator-1 promotes TERT transcription through the MEK/ERK/AP-1 signaling cascade. TERT activator-1 promotes adult neurogenesis and enhances neuromuscular function. TERT activator-1 reduces cellular senescence and systemic inflammation in aged mice, and can be used in the study of aging .
    TERT activator-1
  • HY-145253
    Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH

    		PROTAC Linkers Toll-like Receptor (TLR) Inflammation/Immunology
    Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .
    Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH
  • HY-145254
    Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH

    		Toll-like Receptor (TLR) Inflammation/Immunology
    Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .
    Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH
  • HY-145829
    Tofacitinib Prodrug-1

    		JAK Apoptosis Inflammation/Immunology
    Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis .
    Tofacitinib Prodrug-1
  • HY-145255
    Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH

    		PROTAC Linkers Toll-like Receptor (TLR) Inflammation/Immunology
    Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .
    Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH
  • HY-157456
    RIPK1-IN-19

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .
    RIPK1-IN-19
  • HY-115004
    MM-433593

    		FAAH Neurological Disease
    MM-433593 is a potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) that is orally administered to inhibit pain, inflammation, and related disorders. Pharmacokinetic studies of MM-433593 in macaques revealed a biphasic elimination profile with a rapid distribution phase and a slower elimination phase, with a systemic clearance of 8-11 mL/min/kg. MM-433593 exhibits moderate oral bioavailability (14-21%) and its metabolism primarily involves oxidation of the methyl group on the indole ring, resulting in a variety of sulfate, glucuronide, or glutathione-conjugated metabolites .
    MM-433593
  • HY-156438
    Ruvonoflast

    NT-0796

    		 NOD-like Receptor (NLR) Interleukin Related Neurological Disease
    Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .
    Ruvonoflast
  • HY-155517
    INF200

    		NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation .
    INF200
  • HY-156466
    QL-1200186

    		STAT Interleukin Related IFNAR Inflammation/Immunology
    QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .
    QL-1200186

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: